SARS-CoV-2 neutralizing antibody-Zagazig University-COVID-19

SARS-CoV-2 neutralizing antibody-Zagazig University-COVID-19 is a designation likely derived from a clinical trial outcome measure rather than a distinct therapeutic product. The name refers to the assessment of neutralizing antibody titers in healthcare workers following vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222/Vaxzevria). The associated Phase 3 clinical trial (NCT04830956), sponsored by Zagazig University, evaluated the safety and immunogenicity of AZD1222 in isolation hospital staff in Egypt. AZD1222 is a viral vector vaccine that utilizes a replication-deficient chimpanzee adenovirus (ChAdOx1) to deliver the genetic sequence of the SARS-CoV-2 spike protein. Upon administration, the vaccine induces the host's immune system to produce neutralizing antibodies and T-cell responses that target the spike protein, thereby preventing the virus from entering host cells. This specific entry appears to be a concatenation of the trial's primary immunogenicity endpoint and the lead institution.

Other names

SARS-Cov-2 neutralizing antibody titerSARS-Cov2 neutralizing antibody titerSARS-Cov 2 neutralizing antibody titer